Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUWFD8)

Drug Name

Sacituzumab govitecan Drug Info

Synonyms

hRS7-SN38; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; UNII-M9BYU8XDQ6; hRS 7SN38; Satralizumab linker; IMMU 132; IMMU-132; M9BYU8XDQ6; 1491917-83-9; sacituzumab-govitecan; DA64T2C2IO; CYSTEINYL CL2A-SN-38; SN-38 CYSTEINYL CONJUGATE; DTXSID401335985; EX-A4354; GOVITECAN CYSTEINYL CONJUGATE; F82944; 1535963-91-7; 1796566-95-4

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Urothelial carcinoma	2C92.0	Approved	[1]
Non-small-cell lung cancer	2C25	Phase 3	[2]

Cross-matching ID

PubChem CID: 91668186
TTD Drug ID: DMUWFD8

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tumor associated calcium signal transducer 2 (TACSTD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SKB264	DMSTEFK	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
YH012	DMG3WBJ	Aggressive cancer	2A00-2F9Z	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor associated calcium signal transducer 2 (TACSTD2)	TTP2HE5	TACD2_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website.
2	ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health.
3	Sacituzumab Govitecan: First Approval. Drugs. 2020 Jul;80(10):1019-1025.
4	ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of Biocytogen